Commentary

Podcast

Pharmacy Focus: Oncology Edition- Exploring Pelareorep: A Novel Immunotherapy for Advanced Breast Cancer

Expert discussed the potential of pelareorep, a novel immunotherapeutic agent, in treating advanced or metastatic breast cancer.

About the Expert

Thomas C. Heineman, MD, PhD, is the Chief Medical Officer from Oncolytics Biotech Inc. Heineman earned his MD and PhD in Virology at the University of Chicago.

Pelareorep is a novel immunotherapeutic agent being developed by Oncolytics Biotech Inc. to treat advanced or metastatic breast cancer. Results from the BRACELET-1 study showed pelareorep-based therapy significantly improved progression-free survival and overall survival compared to standard chemotherapy alone in this patient population. Oncolytics plans to conduct a larger registration-enabling study of pelareorep in metastatic breast cancer, as well as evaluate its potential to reduce the risk of disease recurrence in earlier-stage patients. The expert highlighted the unmet need for additional treatment options for breast cancer, especially for patients who progress on existing therapies.

Newsletter

Stay informed on drug updates, treatment guidelines, and pharmacy practice trends—subscribe to Pharmacy Times for weekly clinical insights.

Related Videos
Tired scared retiree man holding chest with anginal symptoms, pallor and diaphoresis at home. Suffering male with cardiac origin pain, prexcordial pressure, arrhythmia risk, urgent medical attention - Image credit: DimaBerlin | stock.adobe.com
Image credit: Sebastian Kaulitzki | stock.adobe.com
Magnified bone marrow biopsy showing plasma cells with irregular nuclei and multiple myeloma tumor cells infiltrating normal hematopoietic tissue
Health and nutrition: the role of glp-1 in diabetes management with apple and syringe - Image credit: Thanayut | stock.adobe.com